Airway Biofilms

@article{Kobayashi2005AirwayB,
  title={Airway Biofilms},
  author={Hiroyuki Kobayashi},
  journal={Treatments in Respiratory Medicine},
  year={2005},
  volume={4},
  pages={241-253}
}
The differentiation of bacterial biofilms in the airway environment, the pathogenesis of airway biofilm, and possible therapeutic methods are discussed. Biofilm diseases that characteristically involve the respiratory system include cystic fibrosis (CF), diffuse panbronchiolitis (DPB), and bronchiectasia with Pseudomonas aeruginosa (P. aeruginosa) infection. There is evidence to suggest that almost all strains of P. aeruginosa have the genetic capacity to synthesize alginate, a main matrix of… 
Fungi in the cystic fibrosis lung: bystanders or pathogens?
Potential role of biofilms in deep cervical abscess.
Microbial biofilm: A matter of grave concern for human health and food industry
TLDR
This review discusses the colonization of pathogenic microorganisms on tissues and medically implanted devices in human beings, and focuses on food spoilage, disease outbreaks, biofilm‐associated deaths, burden on economy, and other major concerns ofBiofilm‐forming pathogenicmicroorganisms in food industries like dairy, poultry, ready‐to‐eat food, meat, and aquaculture.
Update on treatment of pulmonary exacerbations in cystic fibrosis
  • A. Smyth
  • Medicine, Biology
    Current opinion in pulmonary medicine
  • 2006
TLDR
Pulmonary exacerbations in cystic fibrosis are defined and their importance in the pathophysiology and progression of this condition is explained and the importance of prevention and prompt treatment is stressed.
Source Control and Supporting Therapeutics: Integrating Bacterial Invasion, Host Defense, and Clinical Interventions with Source Control Procedures
TLDR
This chapter will address how one may integrate standard source control practices with recent data on potentially controllable elements that may enable host defense success.
Treatment of pulmonary exacerbations in cystic fibrosis
TLDR
Although there is no universal definition of a pulmonary exacerbation in cystic fibrosis, proposed definitions have many similarities and the current recommendations for treatment of pulmonary exacerbations, including the duration and location of treatments are outlined.
Dynamic removal of oral biofilms by bubbles.
Preventing aspiration in the nursing home: the role of biofilm and data from the ICU.
  • P. Drinka
  • Medicine
    Journal of the American Medical Directors Association
  • 2010
...
...

References

SHOWING 1-10 OF 125 REFERENCES
Bacterial biofilm in chronic airway infection.
  • N. Ohgaki
  • Biology, Medicine
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases
  • 1994
TLDR
The results suggest that administration CAM can be one of the therapeutic maneuvers against biofilm bacteria, and the combination of CPFX and CAM was more effective in decreasing the bacterial survival rate than CPFX alone.
Riddle of Biofilm Resistance
  • K. Lewis
  • Biology
    Antimicrobial Agents and Chemotherapy
  • 2001
TLDR
The nature of bacterial biofilm resistance to antimicrobials is the subject of the present minireview and describes an increased resistance of cells to killing.
[Adherence of Pseudomonas aeruginosa to mouse tracheal epithelium--the effect of antimicrobial agents].
  • T. Yamasaki
  • Medicine, Biology
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases
  • 1990
The adherence of bacteria to mucosal surfaces is an important initial event in the pathogenesis of most bacterial infectious diseases. In order to clarify the mechanism of respiratory tract
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.
TLDR
In CF patients with established lung disease, Pseudomonas aeruginosa was located within hypoxic mucopurulent masses in airway lumens, and in vitro studies revealed that CF-specific increases in epithelial O(2) consumption, linked to increased airway surface liquid (ASL) volume absorption and mucus stasis, generated steep hypoxic gradients within thickened mucus on CF epithelial surfaces prior to infection.
Airway biofilm disease: Clinical manifestations and therapeutic possibilities using macrolides
TLDR
In my opinion, “macrolide therapy”, i.e., long-term administration of 14- or 15-membered ring macrolides should be tried in patients with infected cystic fibrosis in Europe and North America due to the apparent therapeutic success of utilizing these macrolide approaches in Patients with Pseudomonas biofilm disease in Japan.
Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response.
TLDR
Because of its ability to prevent attraction of neutrophils to the site of infection, lack of complement activation, and ability to enhance neutrophil oxidative burst, alginate may contribute to the persistence and pathogenesis of chronic P. aeruginosa infection in cystic fibrosis.
Pathogenesis of the pseudomonas lung lesion in cystic fibrosis.
lthough pneumonias in early childhood may be caused by Staphylococcus aureus, Streptococcus pneumoniae, or Hemophilus influenzae, it is the mucoid colonial form of Pseudomonas aeruginosa which is
Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: current status of the host-bacterium interaction.
  • G. Pier
  • Medicine, Biology
    The Journal of infectious diseases
  • 1985
TLDR
Pseudomonas is the harbinger of death for any cystic fibrosis patient, and once it begins to march through the lungs, it multiplies with impunity and sweeps everything in its path.
The involvement of cell-to-cell signals in the development of a bacterial biofilm.
TLDR
The involvement of an intercellular signal molecule in the development of Pseudomonas aeruginosa biofilms suggests possible targets to control biofilm growth on catheters, in cystic fibrosis, and in other environments where P. aerug inosaBiofilms are a persistent problem.
...
...